The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AGENDIA; AstraZeneca; Clovis Oncology; Eisai; Genomic Health; GlaxoSmithKline/Tesaro; Immunomedics/Gilead; Lilly O.; MSD; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; EISAI; Genomic Health; Gilead Sciences; Nykode Therapeutics (Inst); Pfizer; TESARO/GSK
Speakers' Bureau - Amgen; Palleos
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Hope S. Rugo
Consulting or Advisory Role - Blueprint Medicines; Napo Pharmaceuticals; Puma Biotechnology; Scorpion Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pionyr (Inst); Sermonix Pharmaceuticals (Inst); Taiho Oncology (Inst); Veru (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Merck
 
Javier Cortés
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung Bioepis
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; BioInvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; Erytech Pharma; Expres2ion Biotechnologies; Gemoab; Gilead Sciences; GlaxoSmithKline; Hibercell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; Zymeworks
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent.Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
Other Relationship - ARIAD; AstraZeneca; Bayer; Eisai; Guardant Health; Merck Sharp & Dohme; Pfizer; Piqur; Queen Mary University of London; Roche; Roche
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Monica Motwani
Employment - Abbvie; Gilead Sciences; GlaxoSmithKline
Stock and Other Ownership Interests - Abbvie; Gilead Sciences
Patents, Royalties, Other Intellectual Property - A patent on the DR4/5 and KRAS relationship. patent filed by Abbvie and am listed as a co-inventor. No royalties are received.
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences
 
Oh Kyu Yoon
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Jillian Boice
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Luting Zhuo
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Frederik Marmé
No Relationships to Disclose